PAR Pharmaceutical

NYSE: PRX

EST Oct 27 - 19.55USD
Get stock quotes, charts, etc.
ManagementAnnual ReportsNews ReleasesPresentations/WebcastsSEC FilingsParFacts

About ParProductsInvestorsMediaCustomersCareers
Home / Investors

Introduction
Par (NYSE: PRX) has been developing, manufacturing, and distributing generic pharmaceuticals since 1978. Today the Company is the fifth largest generic pharmaceutical company in the U.S.

In 2005, we completed the integration of Kali Laboratories into the company; gained FDA approval of our first specialty pharmaceutical brand (Megace® ES); formed alliances intended to lead toward the development of PAR-101, a novel, narrow-spectrum antibiotic for the treatment of Clostridium difficile-associated diarrhea (CDAD); launched 15 new generic products; and filed 22 new ANDAs with the FDA.

Our goal is to continue the growth that propelled Par into the top echelon of generic drug companies, and simultaneously to move forward with the development of a line of branded specialty pharmaceuticals.

 


Analyst coverage

A detailed two-page corporate fact sheet gives a current overview of Par.

 
Please contact investor relations with investment questions about Par.
 
 
For detailed stock quotes, charts, and related information about Par, please consult current Par data on the NYSE web site.
 
 
Par Begins Shipment of Pravastatin Tablets...
Patrick G. Lepore Named President and CEO of Par...
Par Settle Androgel® Patent Litigation with Unimed...